Catalyst Brief

FDA catalyst calendar

Confirmed PDUFA dates, advisory committees and Phase 3 readouts. Every entry links to its primary source.

November 2026 5

  1. Nov2026
  2. Nov2026
  3. Nov2026
  4. Nov2026
  5. Nov2026

December 2026 33

  1. Dec2026
  2. Dec2026
  3. Dec2026
  4. Dec2026
  5. Dec2026
  6. Dec2026
  7. Dec2026
  8. Dec2026
  9. Dec2026
  10. Dec2026
  11. Dec2026
  12. Dec2026
  13. Dec2026
  14. Dec2026
    Readoutin 14d
    AbbVie — Lutikizumab
    Phase 3 primary completion: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa.
  15. Dec2026
  16. Dec2026
  17. Dec2026
  18. Dec2026
  19. Dec2026
  20. Dec2026
  21. Dec2026
  22. Dec2026
  23. Dec2026
  24. Dec2026
  25. Dec2026
  26. Dec2026
  27. Dec2026
  28. Dec2026
  29. Dec2026
  30. Dec2026
  31. Dec2026
  32. Dec2026
  33. Dec2026
    Readoutin 14d
    Ipsen — Corabotase
    Phase 3 primary completion: A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows.

January 2027 21

  1. Jan2027
  2. Jan2027
  3. Jan2027
  4. Jan2027
  5. Jan2027
  6. Jan2027
    Readoutin 45d
    Novo Nordisk A/S — Insulin icodec
    Phase 3 primary completion: A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes.
  7. Jan2027
    Readoutin 45d
    Hoffmann-La Roche — Afimkibart
    Phase 3 primary completion: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis.
  8. Jan2027
  9. Jan2027
  10. Jan2027
    Readoutin 45d
    AstraZeneca — Dato-DXd
    Phase 3 primary completion: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
  11. Jan2027
  12. Jan2027
  13. Jan2027
  14. Jan2027
  15. Jan2027
  16. Jan2027
    Readoutin 45d
    AstraZeneca — Durvalumab
    Phase 3 primary completion: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer.
  17. Jan2027
  18. Jan2027
  19. Jan2027
  20. Jan2027
  21. Jan2027

February 2027 9

  1. Feb2027
    Readoutin 76d
    Hoffmann-La Roche — Ranibizumab
    Phase 3 primary completion: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome).
  2. Feb2027
  3. Feb2027
    Readoutin 76d
    Pfizer — PF-06821497
    Phase 3 primary completion: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1)..
  4. Feb2027
  5. Feb2027
  6. Feb2027
  7. Feb2027
  8. Feb2027
  9. 28Feb

March 2027 18

  1. Mar2027
  2. Mar2027
  3. Mar2027
  4. Mar2027
    Readoutin 104d
    AbbVie — Risankizumab SC
    Phase 3 primary completion: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease..
  5. Mar2027
  6. Mar2027
  7. Mar2027
    Readoutin 104d
    AbbVie — Upadacitinib
    Phase 3 primary completion: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus.
  8. Mar2027
  9. Mar2027
  10. Mar2027
  11. Mar2027
  12. Mar2027
  13. Mar2027
    Readoutin 104d
    Hoffmann-La Roche — Atezolizumab
    Phase 3 primary completion: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy.
  14. Mar2027
  15. Mar2027
  16. Mar2027
  17. 16Mar
  18. 25Mar

April 2027 10

  1. Apr2027
    Readoutin 135d
    Bayer — Finerenone (Kerendia, BAY94-8862)
    Phase 3 primary completion: A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria.
  2. Apr2027
  3. Apr2027
  4. Apr2027
    Readoutin 135d
    Sanofi — Isatuximab SAR650984
    Phase 3 primary completion: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant.
  5. Apr2027
  6. Apr2027
  7. Apr2027
  8. Apr2027
  9. Apr2027
  10. Apr2027

May 2027 7

  1. May2027
  2. May2027
  3. May2027
  4. May2027
  5. May2027
  6. May2027
  7. May2027

July 2027 1

  1. H22027

Take the calendar with you

Subscribe once and new dates and changes appear in Google Calendar, Apple Calendar or Outlook automatically.
Subscribe to calendar feed